ClinicalTrials.gg
CompletedNCT00784680Updated May 1, 2009

ATAC - Quality of Life Sub-Protocol

A Phase 3 interventional study of Anastrozole and Tamoxifen in Quality of Life, sponsored by AstraZeneca. Completed. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2009-05-01.

Sponsored by AstraZeneca · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Study summary

To compare Quality of Life between the ARIMIDEX group, the NOLVADEX group and the ARIMIDEX plus NOLVADEX combination group during the first two years of treatment. (a) To compare the difference in Quality of Life between the ARIMIDEX group and the NOLVADEX group (b) To compare Quality of Life in the ARIMIDEX plus NOLVADEX combination group with the NOLVADEX group for non-inferiority; if non inferiority is concluded, the difference in QOL between these two groups will be assessed.

02

Conditions studied

  • Quality of Life
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for entry into the main ATAC trial 1033IL/0029
  • Completion of a baseline questionnaire

Exclusion criteria

Exclusion Criteria:

  • Excluded from entry into the main ATAC trial (1033IL/0029)
  • If, in the investigators opinion, the patient would be unable to comply with this sub-protocol due to psychiatric or literacy reasons
05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
308 participants (actual)

Study arms

  • Active comparator
    1

    Arimidex 1mg + Nolvadex placebo

    Drug: Anastrozole

  • Active comparator
    2

    Arimidex placebo + Nolvadex 20mg

    Drug: Anastrozole · Drug: Tamoxifen

  • Active comparator
    3

    Arimidex 1mg + Nolvadex 20mg

    Drug: Tamoxifen

Interventions

  • 1mg, orally, once daily

    Also known as: Arimidex

  • 20mg, orally, once daily

    Also known as: Nolvadex

06

What researchers measure

Primary outcomes

  1. Time to withdrawal

  2. Time to recurrence

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1998 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2008
First posted
Nov 4, 2008
Start
Apr 1998
CompletionActual
Apr 2004
Last update
May 1, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00784680
Lead sponsor
AstraZeneca
First posted
Nov 4, 2008
Start date
Apr 1998
Completion
Apr 2004
Last update
May 1, 2009

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Tamoxifen

Start the discussion